Evidence map›Paper›PMID 41042468›Full record

SynthesisAnnals of surgical oncology2026

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors According to Clinical Risk in Newly Diagnosed, Advanced Ovarian Cancer: A Meta-analysis of Phase III Clinical Trials.

Gillian Reid-Schachter, Helena C Bartels, Donal J Brennan

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Gillian Reid-SchachterUCD Gynaecological Oncology Group, UCD School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland. gillian.reid-schachter@ucdconnect.ie.
Helena C BartelsNational Maternity Hospital, Dublin 2, Ireland.
Donal J BrennanUCD Gynaecological Oncology Group, UCD School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPoly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy improves progression-free survival (PFS) in patients with advanced ovarian cancer, with greatest benefit observed in patients with BRCA alterations and homologous recombination deficiencies (HRD). This study evaluated PFS benefit of PARP inhibitors according to clinically relevant risk factors. PATIENTS AND

methodsA literature search was performed including Cochrane, Medline, Pubmed, Pubmed Central, clinicaltrials.gov, and Embase from January 2018 to January 2025. This was performed using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Data was extracted and random effect models constructed using Review Manager (RevMan Version 7.2.0 The Cochrane Collaboration). Outcomes were reported as pooled hazard ratios (pHR) with 95% confidence intervals (95% CI). Clinically relevant subgroups were analyzed.

resultsA total of 6 studies comprising 3609 patients were selected for analysis. PARP inhibitors were beneficial regardless of patient age, Eastern Cooperative Oncology Group (ECOG) score, disease stage, timing of surgery, chemotherapy response, or high-risk classification. Patients with visible residual disease (VRD) after primary cytoreductive surgery (pCRS) derived significant benefit (pHR 0.61, 95% CI 0.48-0.77, p-value < 0.001). In contrast, no significant PFS benefit was observed for patients with VRD after interval cytoreductive surgery (iCRS) (pHR 0.63, 95% CI 0.36-1.09, p-value = 0.10).

conclusionsAlthough PARP inhibitors benefit various patient subgroups, our analysis did not demonstrate a PFS benefit in patients with VRD following iCRS. Residual disease status appears to be prognostically important for patients undergoing iCRS with maintenance PARP inhibitors. Further analyses of clinical risk factors stratified according to genetic subgroup is required.

trial registrationProspero 2025 CRD420251007940, available at: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251007940.

Indexed as

Ovarian NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsClinical Trials, Phase III as TopicFemaleHumansPrognosisProgression-Free SurvivalRisk FactorsSurvival RatePoly(ADP-ribose) Polymerase InhibitorsClinical risk factorsCytoreductive surgeryOvarian cancerPARP inhibitorsPostoperative residual diseaseProgression-free survival

Identifiers

PMID41042468

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.